Category - cumshot
The epidermal growth factor receptor (egfr) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (tnbc) and inflammatory breast cancer (ibc) overexpress egfr. Thus, egfr inhibitors for treatment of breast cancer have been evaluated in several studies. here, we studied the estrogen and anti-estrogen sensitivity of human breast cancer mcf7 cells that have a moderate, retroviral-mediated, ectopic expression of epidermal growth factor receptor (mcf7-egfr). Proliferation of mcf7-egfr and parental cells was induced by 17-estradiol (e2), epidermal growth factor (egf) or a combination of these. The epidermal growth factor receptor (egfr erbb-1 her1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (egf family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the erbb family of receptors, a subfamily of four closely related receptor tyrosine kinases egfr (erbb-1), her2neu (erbb-2), her 3. Mutations in egf r have since been associated with a number of different cancers including non-small cell lung cancer, breast cancer, metastatic colorectal cancer and glioblastoma. Activation of egf r leads to increased cell proliferation and cell growth and decreased programmed cell death (apoptosis). Breast cancer is the most common type of cancer for women worldwide with a lifetime risk amounting to a staggering total of 10. It is well established that the endogenous synthesis of insulin-like growth factor (igf) and epidermal growth factor (egf) polypeptide growth factors are closely correlated to malignant transformation and all the steps of the breast cancer metastatic cascade. mda-468, a human breast cancer cell line with a high number of epidermal growth factor (egf) receptors, has an amplified egf receptor gene and is growth inhibited by egf. Here, we show that tfcp2 is a potent factor essential for emt, stemness, and metastasis in breast cancer. Tfcp2 directly bound promoters of egf and tgf to regulate their expression and stimulate autocrine signaling via egfr. These findings indicate that tfcp2 is a new antimetastatic target and reveal a novel regulatory mechanism in which a. Breast cancer cells resistant to the pure steroidal er antagonist fulvestrant (fulv) demonstrate increased activation of epidermal growth factor receptor (egfr) family members and downstream erk signaling. In this study, we investigated the effects of fulv on egfr signaling and ligand regulation in several breast cancer cell lines. Aberrant epidermal growth factor receptor (egfr) signaling is a major characteristic of many human malignancies including breast cancer. Since the discovery of egf in 1960s and its receptor in 1980s, our understanding of the egfegfr pathway has been significantly advanced and consequently, egfr is considered as a major oncogenic factor and an attractive therapeutic target. egf induces emt through erk12-phospho-smad23-snail signaling pathway in mda-mb-231 breast cancer cells a. Immunofluorescence staining of e-cadherin expression, cells were treated with or without 30 ngml of egf for 48 h.